AMG
49
14
NAVI
33
-8
KSS
38
2
NWSA
71
2
URBN
75
8
MA
62
2
GWW
48
-2
HIG
50
2
CLX
62
-3
DIS
68
-2
PCG
61
2
VZ
22
-2
C
51
3
AON
28
2
EL
27
2
FDX
33
-11
ACN
50
-6
RL
75
2
UNM
70
3
AVGO
76
2
AMG
49
14
NAVI
33
-8
KSS
38
2
NWSA
71
2
URBN
75
8
MA
62
2
GWW
48
-2
HIG
50
2
CLX
62
-3
DIS
68
-2
PCG
61
2
VZ
22
-2
C
51
3
AON
28
2
EL
27
2
FDX
33
-11
ACN
50
-6
RL
75
2
UNM
70
3
AVGO
76
2
Financhill
Back

Cidara Therapeutics 10K Form

Buy
58

CDTX
Cidara Therapeutics

Last Price:
$23.39
Seasonality Move:
12.86%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive CDTX News And Ratings

See the #1 stock for the next 7 days that we like better than CDTX

CDTX Financial Statistics

Sales & Book Value

Annual Sales: $63.9M
Cash Flow: $-36.8M
Price / Cash Flow: 0
Annual Sales: $16.41
Price / Book: 2.21

Profitability

EPS (TTM): -25.36000
Net Income (TTM): $-120.7M
Gross Margin: $62.4M
Return on Equity: -443.37%
Return on Assets: -134.09%

Cidara Therapeutics Earnings Forecast

Key Cidara Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 5 years for CDTX is 97.62%.
  • The Selling, General & Administrative Expenses for CDTX have been equal to 28.69% of Gross Profit Margin.
  • The Research & Development expenses have been 107.24% of Revenue.
  • The Interest Expense is 0.00% of Operating Income.
  • Per Share Earnings over the last 11 years have been positive in 6 years.

Cidara Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: CDTX
CUSIP: 171757
Website: cidara.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 4.25
Quick Ratio: 4.21

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

CDTX Technical Analysis vs Fundamental Analysis

Buy
58
Cidara Therapeutics (CDTX) is a Buy

Is Cidara Therapeutics a Buy or a Sell?